A study of a new medicine (fazpilodemab) in people with a type of liver disease called non-alcoholic steatohepatitis or NASH

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

Metabolic Disorder
Non Alcoholic Steato-Hepatitis
Kidney Disorder
Chronic Kidney Disease

For Medical Professional
Results
Download
Print

Basic Details

Sponsor Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)

Phase Phase 2

Study Identifier NCT04171765, GC41033

Condition Non-alcoholic Steatohepatitis

Official Title A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis

Study Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).

Eligibility Criteria

Gender

All

Age

≥18 Years & ≤ 75 Years

Healthy Volunteers

Inclusion Criteria

Confirmed diagnosis of NASH as documented through liver biopsy performed no more than 6 months before randomization, defined according to NASH CRN criteria along with a NASH CRN fibrosis score between F2 and F3
Hepatic steatosis on MRI (>= 8% average PDFF) prior to randomization

Exclusion Criteria

History of any liver disease other than NASH, except for resolved, self-limited illnesses such as Hepatitis A or E, and previous Hepatitis C
Weight gain > 10% or loss > 5% within 3 months prior to randomization
History of liver transplantation
Current or history of significant alcohol consumption

The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Results Disclaimer

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A study of a new medicine (fazpilodemab) in people with a type of liver disease called non-alcoholic steatohepatitis or NASH

Basic Details

Study Summary

Eligibility Criteria

What is Clinical Research?

Study results

LPS GC41033 Final Results February 2024 English (PDF, 0.2 MB)

LPS GC41033 Final Results February 2024 French (PDF, 0.2 MB)

LPS GC41033 Final Results February 2024 Spanish (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A study of a new medicine (fazpilodemab) in people with a type of liver disease called non-alcoholic steatohepatitis or NASH

For the latest version of this information please go to www.forpatients.roche.com